anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an alpha-glucosidase inhibitor containing a specific enopyranose derivative or its salt as an active ingredient, useful as a reagent for studying glucoprotein sugar chain processing and a medicine for treating viral diseases such as metastasis and AIDS, diabetes mellitus, etc. CONSTITUTION:This alpha-glucosidase inhibitor contains an enopyranose derivative of formula I (R<1> and R<2> each is H or an alkyl; R<3> is H or an acyl; R<4> is OH, an acyloxy or R<3> and R<4> together form a single bond; X is H or an acyl) or its salt as an active ingredient. As the compound of formula I as the active ingredient, especially, an enopyranose derivative expressed by formula II or formula III or its salt is preferably used. In the compound of formula I, a combination in which R<1> is H or an alkyl and R<2> is an alkyl and X us H or an acyl is preferable. Further, the compound of formula I in which X is furan carbonyl or thiophene carbonyl is preferable. This alpha-glucosidase inhibitor is useful as a medicine for treating hyperlipemia, inflammatory diseases, autoimmune diseases, rejection in organ transplantation, allergic diseases, etc., especially as metastasis inhibitor.
Environmental Monitoring Program for Enterovirus (1) Case Collection. The studies cases include patients who were suspected of having enterovirus illnesses, such as HFMD and herpangina. Institutional review board approval was obtained from the Hospital for this study and informed consent was obtained from all patients or their parents. (2) Questionnaire. questionnaire based interviews were used to collect information about the family members, including demographic data, the number of bedrooms in the house, amount of contact time with the patient, presence and pattern of current or recent signs and symptoms. (3) Patient and culture samples. Laboratory evidence of enterovirus infection was defined as the isolation of enterovirus from a throat , and rectal swab sample. (4) Environmental Sampling. (a) Air sampling. For the filter/real-time qPCR assay, the air in each ward was filtered through a 37-mm-diameter Nuclepore filter (Costar, Cambridge, MA), which is a track-etched polycarbonate filter consisting of a polycarbonate membrane with straight-through pores of uniform size (0.4 μm). The filters were supported by cellulose pads and loaded into open-face three-piece plastic cassettes. The pump and filter apparatus were placed within 1 m from the patient's bed on an adjacent nightstand. (b) Surface sampling Regarding surface sampling, surfaces of environment and equipment were sampled with moistened sterile cotton swabs.
NEW MATERIAL:A recombinant human hepatic parenchymal cell growth factor. USE:Culture reagents for hepatic parenchymal cells, hepatic regeneration promoters, fundamental research regents for hepatic function, carcinogenic research reagents for hepatic cancer, clinical diagnostic reagents for hepatopathy and treating agent for the hepatopathy. PREPARATION:For example, rat liver RNA is extracted from a rat liver by a guanidine thiocyanate method and an mRNA is separated by an oligodT cellulose column chromatography, and used as a template to synthesize a cDNA using a reverse transcriptase, The resultant cDNA is then integrated into a plasmid, etc., to prepare a cDNA library, which is subsequently screened with a probe to select a clone containing a DNA capable of coding a human hepatic parenchymal cell growth factor. The DNA is then collected, treated with a restriction enzyme and linked to an expression vector. The obtained vector is subsequently transduced into a host cell. Transformation is carried out and the resultant transformant is cultured to afford the objective recombinant human hepatic parenchymal cell growth factor.
Studying inflammatory responses induced by vaccination can contribute to a more detailed understanding of underlying immune mechanisms in lumpfish (Cyclopterus lumpus). Tissue samples from lumpfish intraperitoneally immunized with a divalent oil-adjuvanted vaccine (Aeromonas salmonicida and Vibrio salmonicida) at water temperatures of 5, 10, and 15°C were collected at 630 day degrees and 18 weeks post injection. The relative amount of secretory and membrane-bound immunoglobulin M (IgM) gene transcripts in the head kidney was determined by qPCR. Vaccine-induced inflammatory lesions were assessed on histological sections of abdominal pancreatic/intestinal tissue from vaccinated fish in all three temperature groups. Inflammatory cells forming dense aggregations in lesions showed proliferative activity, many of which were identified as eosinophilic-granulocyte-like cells. IgM+ cells were scattered in inflammatory tissue dominated by connective tissue, showing no difference in numbers between lesions from fish vaccinated at 5, 10, and 15°C. Relative gene expression analysis of secretory and membrane-bound IgM revealed low overall expression in the head kidney of vaccinated fish at both 630 day-degrees and 18 weeks post injection. The results of this study indicate that the vaccine stimulated prolonged local inflammatory responses at the injection site, which were not influenced by temperature.
All patients in this group are routinely administered general anesthesia. After extubation, the subcostal transverse abdominis area block was directed laterally along the rectus abdominis muscle by finding the linea alba under the xiphoid region under ultrasound guidance with a 22G echogenic block needle, and 20 ml (8 ml 0.5% bupivacaine, 7 ml prilocaine) into the fascia between the rectus abdominis and transverse abdominis muscles. , 5 ml of saline) drug mixture will be performed by the anesthesiologist in charge of that day, who is not aware of the observational measurement to be made, if there is an indication, as a blind practitioner.
Spontaneous coronary artery dissection (SCAD) is a non-atherosclerotic cause of myocardial infarction and sudden cardiac death in young individuals without significant cardiovascular risk factors. The etiology of SCAD appears to be multifactorial and is often precipitated by physical and emotional stress superimposed on underlying arteriopathy, connective tissue disorders, systemic inflammatory disorders, genetic factors, and hormonal influences. There are no current societal guidelines to stratify young soldiers' risk of developing SCAD. Diagnosis typically requires invasive coronary artery angiography which is largely unavailable in stations with limited medical resources. Furthermore, young patients with SCAD often present with atypical cardiac symptoms, such as heartburn leading to the misdiagnosis of gastroesophageal reflux disease and a delay in diagnosis and management. We present a 21-year-old active duty male who was transferred from Okinawa, Japan to a tertiary military medical center for evaluation of hypercoagulable conditions after CT revealed non-obstructing portal venous thrombosis extending to right hepatic vein, splenic vein thrombosis with splenic infarct, and bilateral wedge-shaped renal infarct. Extensive work-up ultimately revealed mid-left anterior descending spiral dissection with transmural infarct of inferior, anteroseptal, and inferoseptal wall resulting in the formation of left ventricular thrombus, subsequently causing thromboembolism to multiple organs. This case demonstrates the ramifications of SCAD when diagnosis and management are delayed and serve as a poignant reminder for all providers to include SCAD in the differential diagnosis for young soldiers with atypical chest pain.
The study consists of two arms in this crossover design study. The first arm of this study will receive intravenous and oral NAC, which is a strong antioxidant that increases brain glutathione, which may be beneficial in PD. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement and also is available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. Laboratory studies have displayed some benefits to use of NAC, such as its potential to counteract intracellular damage that leads to dopaminergic neuron death. It also has the potential to reduce markers of oxidative damage, protect against dopamine cell death from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity, and to increase glutathione in blood, which might be useful in preventing oxidative damage in PD patients. The second arm will be a waitlist control receiving standard PD care. It should be noted that both arms will receive standard of care treatment for PD which will be augmented with NAC. A key component of this study is to evaluate the effects of NAC on dopamine, using PET imaging with FDOPA. Specifically, we will plan to study changes in dopamine levels before and after receiving approximately nutritional support with NAC.. This will allow us to evaluate whether NAC helps to support dopamine function. FDOPA PET imaging will be conducted at baseline and then after the nutritional support or standard of care for the waitlist arm. Then the waitlist group will receive NAC and the arm that received NAC initially will be crossed over to a standard of care group. FDOPA imaging will be conducted at the end of that period.

For evaluation of the dopamine function, \[F-18\] Fluorodopa (FDOPA), dose (5-10 millicurie (mCi), ± 20%) will be injected intravenously into an antecubital vein. Subjects will be premedicated with 200 mg of carbidopa orally approximately one hour prior to injection.

FDOPA has been available for over 30 years but has not been previously approved for commercial use by the FDA.We will be obtaining the FDOPA from the University of Pennsylvania cyclotron that has produced FDOPA for many Investigational New Drug applications (INDs) It will also be beneficial to assess whether there are specific changes in levels of different molecules that are related to energy consumption and oxidative stress. Proton MR spectroscopy (1H-MRS) has been previously performed in Parkinson's disease (PD) and parkinsonian syndromes to evaluate in vivo concentrations of basal ganglia and cerebral cortex metabolites such as N-acetylaspartate (NAA), choline (Cho), and creatine (Cr). We plan to include MRS as an additional biomarker to evaluate the potential effects of the nutritional supplements and/or NAC on oxidative stress and cerebral activity in PD patients.
A compound and method are provided for combining a chemotherapeutic drug with a polyion polymer for selective chemotherapy delivery. A glucose solution is combined with the polyion polymer, which allows the glucose solution and polyion polymer to be infused into a body containing cancer cells. The glucose solution is capable raising the pH level of cancer cells to a pH of 6.0 to 4.0. The polyion polymer reacts to different pH levels. The acidic environment of the cancer cell causes the polyion polymer to take on an “open line” form, thereby releasing the chemotherapeutic drug to selectively attack the cancer cells. In the neutral or low pH environment of healthy cells the chemotherapeutic drug is retained in an inactive form within the polyion polymer, which remains in the globular closed form, thereby leaving healthy tissue undamaged.
This is a pilot study in two parts that aims to determine the feasibility of conducting PET-MR imaging using \[18F\]-FBA-A20FMDV2 (\[18F\]-IMAFIB) and novel PET-MR imaging in patients with SH and CASH in CRC hepatic metastatic disease. A combination of factors will be used to determine the feasibility of \[18F\]-IMAFIB PET-MR imaging including visual adequacy of the PET-MR image, adequate signal to noise ratio and the ability to evaluate changes in \[18F\]-IMAFIB uptake and PET-MR parameters. In addition, the operational feasibility of this study will be assessed. Up to 10 patients will be evaluated in this study. The number of patients to be included in this heterogeneous cohort of patients has been based on feasibility considerations taking into account recruitment rates and not on any formal statistical evaluation. An adaptive study design will be used with patients with imaging results being continuously assessed. In the first part 3 patients will be imaged, 2 with severe biopsy proven SH and one with severe CASH. Thereafter, depending on the imaging results, the second part will include up to 7 patients with mild to moderate SH and those with mild to moderate CASH. If there are major changes in the imaging protocol an amendment to the ethics committee will be submitted.
Atorvastatin is metabolized by cytochrome P450 3A4. Concomitant administration of atorvastatin with strong inhibitors of CYP3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of interaction and potentiation of effects depend on the variability of effect on CYP3A4. Because LYPQOZET contains atorvastatin, the risk of myopathy during treatment with LYPQOZET is increased with concurrent administration of:

Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of 80 mg atorvastatin with clarithromycin (500 mg twice daily) compared to that of atorvastatin alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking clarithromycin, caution should be used when the LYPQOZET dose exceeds 10/20 mg [see Warnings and Precautions (5.1) and Dosage and Administration (2.3)].

Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of atorvastatin alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of LYPQOZET should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing LYPQOZET and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of LYPQOZET should not exceed 10/20 mg and should be used with caution [see Warnings and Precautions (5.1) and Dosage and Administration (2.3)]. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, the dose of LYPQOZET should not exceed 10/40 mg daily and close clinical monitoring is recommended.

Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)]. Therefore, in patients taking itraconazole, do not use a LYPQOZET dose that exceeds 10/20 mg [see Warnings and Precautions (5.1) and Dosage and Administration (2.3)].
The utility model relates to a Chinese medicine plaster for enhancing body resistance and a preparing method. The Chinese medicine plaster for enhancing body resistance is prepared mainly by raw medicines with the weight portions that wind ginseng with is of 2.5 to 10, aweto is of 1.5 to 6, dahurian angelica root is of 1 to 4, psoralea fruit is of 1 to 4, eaglewood is of 0.5 to 2 and schisandra is of 2.5 to 10. The preparing method has the steps that the wild ginseng, the aweto, the angelica dahurica root, the psoralea fruit, the eaglewood and the schisandra are pulverized into fine powder with the meshes of 50 to 200 by mixture ratio and then are uniformly mixed; the mixed medicament is added with ordinary umbilical paster solvent to be made into round cake shape, and then a gel used as a platform for carrying the medicament; after sterilization, the medicament is packed into finished product in a vacuum packing mode. The ordinary umbilical paster solvent is at least one kind of honey, or Vaseline or ginger juice, and the gel is common cloth adhesive or medical adhesive dressing cloth. The preparation of the present invention is made of pure Chinese medicine, and has no toxin and side effect. With the treating method of umbilical application, the Chinese medicine plaster for enhancing body resistance has the characteristics of convenient operation, obvious effect, symptom disappearing or improvement, etc.
The invention discloses a system and a method for packaging and distributing game chemical medicines. The innovative playable smart packaging system and method provides a variety of incentives for patients and related teams to take medications on time and in the correct dosage. The system includes a monitored drug dispensing device in communication with a plurality of computing devices or smart phones. A signal is transmitted to the computing device each time a patient dispenses a medication from the dispensing device. Upon receiving the signal, the computing device records a dispensing event, calculates a specific "score" for the event, and reports a cumulative "score" for successful dispensing of the medication for the patient. If the dispensing event signal is not received on time, the system sends a medication intake reminder to the patient. Accumulating points by correctly taking prescribed medications allows the patient and/or team to be eligible for various benefits.
Pharmaceutical composition comprises an active substance combination of at least an isoflavone or isoflavone-glycoside and/or their salts or solvates and at least a peptide or its derivative with 2-5 amino acids and/or its salts or solvates, where at least 2 amino acids side chain exhibits negatively charged pH 7. Independent claims are included for: (1) a composition comprising an active agent combination that comprises at least one mineral salt, preferably iron salt, and at least a peptide or its derivative; and (2) a procedure for manufacturing medicament, preferably for inhibiting thrombocyte aggregation comprising providing an active agent; and providing the peptide derivative and mixing. ACTIVITY : Cardiant; Analgesic; Antianginal; Osteopathic; Cytostatic; Hypotensive; Antilipemic; Antiarteriosclerotic; Cerebroprotective; Vasotropic; Antidiabetic; Hemostatic; Gastrointestinal-Gen. MECHANISM OF ACTION : Thrombocyte aggregation inhibitor. The ability of the composition to inhibit thrombocyte aggregation was tested in patient. The result showed that the composition (genistein 50 mu M and glutamic acid dipeptide 250 mu M) significantly inhibited the thrombocyte aggregation than genistein alone.
Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
The thymus derives from the third branchial pouch, which migrates to the mediastinum through the central region of the neck. During the migration, particles split off and develop separately. The prevalence of ectopic thymus is 20-40%. The purpose of this retrospective case series study was to investigate the prevalence of embryological tissue remnants in the central region, in patients treated for thyroid lesions. Between January 1 2018 and September 1 2020, 84 patients who underwent central neck dissection were selected. Clinicopathological data as age, gender, histopathological result and TNM stage were analyzed. Ectopic tissue in the central neck region was discovered in 28 cases. The prevalence of ectopic lesions showed increase in Stage I thyroid carcinomas. There was no significant correlation with patients' age, gender, or with the stage. We emphasize the clinicopathological role of ectopic tissues, which can occur in the central region of the neck.
Breast cancer is sensitive to a range of chemotherapeutics agents, but despite initial sensitivity, resistance typically emerges, resulting in disease relapse or progression. Exploration of novel classes of agents in the treatment of breast cancer is therefore in urgent need. Vorinostat or SAHA, a potent inhibitor of histone deacetylase (HDAC) activity, represents a novel class of anti-cancer agents in early stages of development. Vorinostat is active in inducing differentiation, cell growth arrest, and/or apoptosis in a wide variety of transformed cells in culture, and has shown activity against breast cancer in cell lines and animal models. Exploratory pharmacokinetic analysis has demonstrated that oral Vorinostat has excellent bioavailability. Oral Vorinostat has been administered to more than 300 patients enrolled in completed or ongoing clinical studies. The maximum tolerated dose (MTD) is 400 mg q.d. or 200 mg b.i.d. continuously, or 300 mg b.i.d. x 3 consecutive days per week. Dose-limiting toxicities (DLT) are non-hematologic (anorexia, dehydration, diarrhea and fatigue), that resolve quickly once drug administration is interrupted. This study will evaluate the safety and efficacy of Vorinostat in breast cancer patients who have failed anthracyclines and taxanes, and if proven active, will add an important new class of agents to the treatment armamentarium of breast cancer. The study will be divided into 2 phases: phase I to determine the MTD in our population, starting with 400mg q.d. continuously, with progressive dose decrements in the event of DLT; and phase 2 to determine efficacy of Vorinostat at MTD in 12-37 evaluable patients. Correlative studies (pharmacokinetics, pharmacogenetics, plasma proteomics, tumor histone acetylation, genomics and proteomics) will be carried out to identify markers that will predict treatment response and/or toxicity to Vorinostat, to achieve the future goal of tailored therapy.
Current posterior instrumentation devices employ pedicle screw and hook based systems to correct spinal deformity. Challenges remain for surgeons to appropriately contour the rods used to achieve the desired correction. The current practice is for the surgeon to intra-operatively contour the rod using various bending tools based on the appearance of the spine. The surgeon visually estimates the amount of bend needed and contours the rod accordingly. Changes in rod contours during implantation from the forces of correction limit the ability to achieve desired and optimal corrections. This is possibly related to both inaccurate bending estimates as well as techniques that affect the peri-implantation rod contours. These phenomena may lead to complications including but not limited to failure of hardware, coronal and/or sagittal spinal imbalance, and adjacent segment pathology or failure. The ability for the surgeon to pre-operatively calculate the proper bends to generate a predictable correction may improve patient outcomes by achieving better overall correction, better coronal and sagittal balance, reduce adjacent segment pathology.The purpose of this study is to evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool,Surgimap Spine to generate a template for manual rod contouring. The study will correlate the post-operative changes in rod contours with the correction achieved in spinal deformity. The pilot study will be used to validate the model for a prospective, randomized, multi-center, study of statistical power to compare the results of pre-operatively determined rod contours to intra-operatively determined rod contours
Provided herein is a gene therapy for GLUT1 Deficiency Syndrome and related disorders using a recombinant adeno-associated virus (rAAV) virion as a vector to express an GLUT1 protein or functional variant thereof. The capsid may be an AAV-BR1 capsid or a functional variant thereof. Other promoters or capsids may be used. The rAAV virion may use an endothelial-specific promoter,  e.g. , a FLT-1 promoter. Further provided are methods of treatment, such as by intracerebrally and/or intravenously of the rAAV virion, and other compositions and methods.